Abstract Nuclear receptors are ligand-activated transcriptional regulators of several key aspects of renal physiology and pathophysiology. As such, nuclear receptors control a large variety of metabolic processes, including kidney lipid metabolism, drug clearance, inflammation, fibrosis, cell differentiation, and oxidative stress. Derangement of nuclear receptor regulation, that is, mainly due to obesity may induce metabolic syndrome, may contribute to the pathogenesis and progression of chronic renal disease and may result in end-stage renal disease. This places nuclear receptors at the forefront of novel therapeutic approaches for a broad range of kidney disorders and diseases, including glomerulosclerosis, tubulointerstitial disease, renal lipotoxicity, kidney fibrosis, and hypertension. This review focuses on the importance of the transcription factors peroxisome proliferator-activated receptor alpha, peroxisome proliferator-activated receptor beta, peroxisome proliferator-activated receptor gamma, liver X receptors, farnesoid X receptor, and the pregnane X receptor/steroid and xenobiotic receptor (PXR) on the physiology and pathophysiology of renal diseases associated with obesity and metabolic syndrome.
Cellular lipid homeostasis is regulated by the influx, synthesis, and efflux of lipids (Kim et al. 2009 ). The accumulation of triglycerides and cholesterol in the kidney is mediated by increased expression and activity of the transcriptional factors sterol regulatory element-binding proteins 1 and 2 (SREBP-1 and SREBP-2), which are regulators of fatty acid and cholesterol synthesis. Additionally, these alterations are accompanied by renal mesangial expansion, accumulation of extracellular matrix proteins, and activation of oxidative stress, pro-inflammatory cytokines, and profibrotic growth factors that mediate increases in fatty acid and cholesterol synthesis (Jiang et al. 2005) .
Although they are poorly understood in the setting of altered metabolic conditions in obesity, several hormonal and metabolic factors have been shown to contribute to the pathogenesis of obesity-related renal disease, including oxidative stress, angiotensin II, inflammatory cytokines, and hyperinsulinemia/insulin resistance. In addition, it has also been proposed that nuclear receptors, which are master regulators of lipid and carbohydrate metabolism, play an important pathogenic role as regulators of renal lipid accumulation. Nuclear receptors and their target genes and coregulators have been shown to play a crucial role in the development of alterations in normal kidney physiology (Levi et al. 2011) . Nuclear receptors are transcription factors that play an important role in regulating gene expression (Francis et al. 2003) and are members of a large superfamily of evolutionarily related DNA-binding transcription factors that control programs involved in a broad spectrum of physiological phenomena (Germain et al. 2006) . From the phylogeny study of nuclear receptors, it has been established that they emerged in the earliest of metazoan evolution, long before the divergence of vertebrates and invertebrates (Escriva et al. 1997; Owen and Zelent 2000) (Table 1) .
Historically, the most studied nuclear receptors have been those for steroid hormones, particularly for estrogens, androgens, progesterone, glucocorticoids, and mineralocorticoids. These receptors, typically bind with high affinity (Kd in the nanomolar range) and high specificity to their specific ligands and form homodimers that interact with the DNA to activate the expression of specific genes (Chawla et al. 2001; Francis et al. 2003) . However, attention has turned to several nuclear receptors whose endogenous ligands, target genes, and physiological functions are not known. Hence, traditionally, they are known as ''orphan receptors'' (Chawla et al. 2001) . In contrast with the classic steroid receptors, the orphan receptors bind their ligands with a lower affinity (Kd in the micromolar range) and have a broader repertoire of ligands. However, once a natural ligand has been discovered for an orphan nuclear receptor, the receptor is no longer considered to be an orphan. During the last years, endogenous ligands for several of the orphan receptors have been discovered, and they are classified as adopted orphan nuclear receptors (Table 1) . However, there are some orphan nuclear receptors whose ligands are still unknown. Thus, several of the adopted orphan nuclear receptors are considered as natural sensors, since they are capable to bind a large diversity of ligands, most of them are essential biomolecules. Changes in the concentration of these metabolites are signals to promote metabolic changes that are sensed by the nuclear receptors to trigger modifications in the rate of transcription of specific genes with the final goal to maintain homeostasis.
At present, 48 genes in humans (Benoit et al. 2006 ) are known to belong to the family of nuclear receptors, and there is a notable structural similarity among them ( Fig. 1 ) (Germain et al. 2006; Ruan et al. 2005) . Nuclear receptors have a common structure consisting of the following domains: (1) an NH 2 -terminal ligand-independent activation domain, called AF-1, for interaction with cofactors (A/B domain); (2) a central DNA-binding domain, which consists of two zinc finger motifs and allows binding to distinct recognition sites of the DNA known as hormone response elements (DBD or C domain); (3) a hinge region (D domain); and (4) a C-terminal ligand-binding domain (LBD), which is unique to each nuclear receptor and allows for distinct binding, receptor dimerization, and coregulator interactions (E/F domain) (Wagner et al. 2011; Sonoda et al. 2008) .
After the nuclear receptors bind with their specific ligands, they bind to certain regions of the genome that are known as DNA-response elements that regulate the rate of transcription of many genes (Table 2) (Rosenfeld and Glass 2001; Cortes et al. 2005) . Nuclear receptors interact with the corresponding response elements to form homodimers or heterodimers. They use several partners, but mainly use the 9-cis-retinoic acid receptor (RXR). Binding of dimerized nuclear receptors to specific response elements can promote and/or enhance transcription (Germain et al. 2006) . Because of the essential roles nuclear receptors play in virtually all aspects of mammalian development, metabolism, and physiology, a dysfunction of signaling controlled by these receptors is associated with reproductive, proliferative, and metabolic diseases (Table 1) (Germain et al. 2006) . Additionally, nuclear receptors can recruit several proteins known as coregulators, which determine the function of a specific nuclear receptor (Table 2) (Ruan et al. 2005; Francis et al. 2003) . The protein level of the coregulator is crucial for driving transcription that is mediated by nuclear receptors. Several coregulators are activated or repressed by various intracellular signaling pathways and posttranslational modifications (Ruan et al. 2005) . Because coregulator levels in cells are normally tightly regulated, a small change in their concentration can greatly influence the function of a nuclear receptor, and it is believed that over-or underexpression of coregulators can contribute to the development of certain pathologies (Lonard et al. 2007 ). Some nuclear receptors are considered to be metabolic nuclear receptors as defined by Francis et al. because they are activated by nutrients, diet metabolites, or drugs and act as metabolic and toxicological sensors. These nuclear receptors allow the body to adapt to environmental changes by inducing the appropriate metabolic genes and pathways (Francis et al. 2003) . The metabolic nuclear receptors are master regulators integrating the homeostatic control of (a) energy and glucose metabolism through peroxisome proliferator-activated receptor gamma (PPAR c); (b) fatty acid, triglyceride, and lipoprotein metabolism via PPAR a, d, and c; (c) reverse cholesterol transport and cholesterol absorption through the liver X receptors (LXRs); (d) bile acid metabolism through the farnesoid X receptor (FXR) and LXRs; and (e) the defense against xeno and endobiotics by the pregnane X receptor/steroid and xenobiotic receptor (PXR) ( Table 1) .
Because the binding of small, lipophilic ligands that include hormones and metabolites such as fatty acids, bile acids, oxysterols, and xeno and endobiotics controls the activity of these nuclear receptors, when the concentrations of these metabolites are modified, alterations in the homeostasis of the signaling pathways may trigger various diseases (Ruan et al. 2005) , several of which are associated with the development of degenerative chronic diseases, including hypercholesterolemia, insulin resistance, and obesity.
Recently, obesity has increased dramatically worldwide, and it has been associated with a high incidence of metabolic syndrome (Ruan and Guan 2009 ). This syndrome is defined as a constellation of physiological changes including hypertriglyceridemia, hyperglycemia, and hypo alpha-lipoproteinemia, which are mainly caused by excess calorie intake that results in excess body fat. Metabolic syndrome has been strongly associated as a risk factor for the development of chronic kidney disease and end-stage renal disease (Hsu et al. 2006; Iseki et al. 2004) .
The progression of renal diseases is accompanied by inflammation, metabolic disorders of the glucose and lipid metabolism, hypertrophy and apoptosis, matrix expansion and oxidative stress. Thus, the aim of the present review is to summarize the current knowledge and the potential role of nuclear receptors as metabolic regulators involved in some of the abnormalities associated with the development of renal diseases in the setting of obesity and metabolic syndrome.
The role of PPARs in metabolic renal dysfunction
PPARs are nuclear hormone receptors that stimulate transcription of specific genes by binding to specific DNA sequences. The three PPAR subtypes are products of the distinct genes commonly designated as PPARa, PPARc, and PPAR b/d, or merely d (Berger et al. 2005 ). These lipid sensors are ''master'' transcriptional regulators of nutrient metabolism and energy homeostasis that modulate the expression of unique groups of genes. The PPARs usually heterodimerize with another nuclear receptor, the RXR, to form a complex that interacts with specific DNA-response elements within the promoter region of the target genes. Ligand binding can activate this heterodimer complex, which recruits transcription coactivators and regulates the transcription of genes involved in the regulation of lipid and carbohydrate metabolism (Michalik et al. 2006; Moore et al. 2006; Rosen and Spiegelman 2001) . PPARa, PPARc, and PPAR d are differentially expressed in various tissues (Robinson and Grieve 2009) . In general, PPARa is highly expressed in tissues that possess high mitochondrial and b-oxidation activity, including the renal cortex. PPARc is highly enriched in adipose tissue, while lower expression levels are reported in the urinary bladder and kidney. Unlike PPARa and PPARc, low-level expression of PPARd is found ubiquitously in almost every tissue examined. In the kidney, PPARa is abundantly expressed in the proximal tubules and the medullary thick ascending limb, with much lower expression in the glomerular mesangial cells (Ruan et al. 2003; Guan et al. 1997) . PPARc is primarily expressed in the distal medullary collecting ducts, with lower expression in the glomeruli and renal microvasculature ). In the kidney, PPARd is diffusely expressed in the renal cortex and medulla, including medullary interstitial and stromal cells (Guan et al. 1997 ). This differential distribution of the three PPAR isoforms within different tissues may be related to their distinct roles in the kidney. Because the target genes of PPARa, d, and c in many tissues are mainly involved in Genes Nutr (2012) 7:483-498 487 adipogenesis, lipid metabolism, insulin sensitivity, glucose homeostasis, and cell growth and differentiation, PPARs could be target candidates for the modulation of body metabolism.
PPARa
PPARa is highly expressed in the proximal tubules and plays an important role in the metabolic control of renal energy homeostasis (Portilla 2003) . Fatty acids constitute a major source of metabolic fuel for energy production in the kidney. PPARa controls a set of genes essential for fatty acid b-oxidation in the renal cortex and contributes to an appropriate adaptive response to dietary lipids by the kidney. Specifically, PPARa plays a critical role in the regulation of fatty acid transport protein (FATP), which facilitates the uptake of long-chain fatty acids across the plasma membrane and several key enzymes involved in their subsequent catabolism within the cell (Fig. 2) . PPARa has been shown to induce activation of acyl-CoA oxidase (ACO), thiolase, acyl-CoA dehydrogenase, and cytochrome P-450 x-hydroxylase, which are all essential to the b-oxidation of fatty acids within peroxisomes, mitochondria, and microsomes ( Fig. 2) (Schoonjans et al. 1996) . PPARa expression has also been found to be significantly increased in situations of metabolic stress, such as fasting or severe cold, when increased energy production requires the release of fatty acids from adipose tissue (Lemberger et al. 1996) . The kidney response to starvation in PPARa-null mice has been shown to be blunted, supporting this finding (Sugden et al. 2001 ). These observations collectively suggest that PPARa may participate in certain renal pathophysiological settings associated with deregulation of energy homeostasis such as diabetic nephropathy and kidney lipotoxicity (Ruan et al. 2008) . Additionally, PPARa stimulates the expression In an animal model of type I diabetes, the renal expression of PPARd is greatly suppressed, which may contribute to renal lipotoxicity due to reduced fatty acid oxidation. Treatment of mesangial cells with insulin-like growth factor-1 (IGF-1), a cytokine up-regulated in the diabetic kidney, enhanced triglyceride accumulation, possibly by increasing very low-density lipoprotein receptor (VLDLr) expression resulting from PPARd suppression. In addition, PPARd down-regulates the expression of the receptor for advanced glycation end products (RAGE) and proinflammatory cytokines (TNF-a, IL-1 and IL-6) in the kidney of diabetic mice. These finding suggest that the reduction in renal PPARd expression possibly represents an underlying mechanism involved in diabetic kidney injury. Activation of PPARc by prostaglandin J2 or TZD increased LXRa and ABCA1 gene expression in mesangial cells. Interestingly, PPARc is a negative modulator for transcription of both angiotensin II receptor type 1 (AT1 receptor) and leptin genes. Additionally, PPARc agonists can suppress TGFbinduced collagen I and fibronectin production in mesangial cells. In the case of renal disease, the use of PPARc agonists has positive effects on renal hemodynamics and renal injury of lipoprotein lipase (Fig. 2) that it is known to promote the release of fatty acids from lipoprotein particles, as well as their subsequent uptake (Schoonjans et al. 1996) . Several recent clinical studies provide clear evidence that the fibrate class of PPARa agonists confer a renoprotective effect in patients with type 2 diabetes. The renal protective effect of PPARa agonists is apparently multifactorial. In addition to systemically attenuating insulin resistance and dyslipidemia, the agonists may have a direct beneficial action on the kidney. Indeed, PPARa agonists are widely used in the treatment of disorders characterized by elevated levels of plasma lipids. Fibrates exert their positive effect on lipid handling by inducing hepatic uptake and b-oxidation of fatty acids and increasing lipoprotein disassembly, while also conferring beneficial effects on the high-density lipoprotein (HDL) to low-density lipoprotein (LDL) ratio. PPARa activation has also been shown to have antiinflammatory effects. The control of inflammatory pathways by PPARa occurs mainly via repression of target genes caused by negative interference in a DNA-bindingindependent manner (trans-repression) (Zambon et al. 2006) . Although inflammatory processes are important for the initiation of the defense mechanism (Streetz et al. 2001) , they can become deleterious in situations of chronic activation. Fibrates can exert anti-inflammatory effects in patients with atherosclerosis by decreasing plasma levels of cytokines, interleukin 6 (IL-6), tumor necrosis factor a (TNFa), and interferon-gamma (INFc), while decreasing levels of C-reactive protein (CRP) in patients with cardiovascular disease will also result in anti-inflammatory effects (Zambon et al. 2006) . In a study conducted by Li and coworkers, the investigators demonstrated that fenofibrate decreased renal expression of pro-inflammatory factors, tubulointerstitial fibrosis, and interstitial macrophage infiltration in Zucker diabetic rats . Moreover, the anti-inflammatory and anti-fibrotic effect of the PPARa activator was accompanied by a suppression of nuclear factor kappa-light-chain-enhancer of activated B cells (NFjB) and transforming growth factor b1 (TGF-b1), mothers against decapentaplegic homolog 3 (Smad3) in the diabetic kidney (Fig. 2) . Additionally, in a study conducted by Lin et al., PPARa overexpression also inhibited the induction of the activity of NFjB, which was associated with an interaction between PPARa and the NFjB p65 subunit as revealed in immunoprecipitation assays (Lin et al. 2007 ). PPARa agonists (fenofibric acid and eicosapentanoic acid) enhance endothelial nitric oxide synthase (eNOS) expression and nitric oxide (NO) release, which suggests a vasoprotective effect. In other studies, synthetic PPARa activators (fenofibric acid and WY14643) were shown to diminish thrombin-induced and oxidized LDL (ox-LDL)-induced expression of endothelin-1 (Gilde et al. 2003) . PPARa activators can also modify the activation of inflammatory vascular smooth muscle cells (VSMCs) by inhibiting interleukin-1 (IL-1)-induced production of IL-6 and prostaglandins and by reducing the expression of cyclooxygenase-2 (COX-2). Moreover, PPARa activation, in the presence of TNFa and INFc, may promote macrophage apoptosis (Cheng et al. 2010 ).
Regulation of PPARa unmasks an interaction area for coactivators such as cAMP response element binding protein (CREB)-binding protein (CBP) and p300. The latter possesses histone acetyl transferase (HAT) activity that results in chromatin decondensation and PPARa heterodimerization with RXR. The binding of this heterodimer to PPRE on PPARa-containing promoters results in the regulation of expression of the target genes. In addition, PPARa is a substrate for several kinases that are activated by a variety of endogenous or exogenous signals. These kinases include the following: extracellular receptor kinase-mitogen-activated protein kinase (ERK-MAPK), c-Jun N-terminal kinase (JNK) and p38 MAPK, Protein kinase A (PKA), Protein kinase C (PKC), 5
0 -AMP-activated protein kinase (AMPK), and glycogen synthase kinase 3 (GSK3). Recent studies of the SUMOylation of PPARa have reported that SUMOylated hPPARa on lysine 185 results in down-regulation of this transcriptional activity by promoting its interaction with the corepressor NCoR (Pourcet et al. 2010) . Therefore, it is interesting to investigate whether PPARa modifications, including phosphorylation, SUMOylation, and ubiquitination, are involved in inflammation-induced renal failure. Recently, it was demonstrated that adiponectin exerts a protective effect against renal ischemic-reperfusion injury via the prostacyclin-PPARa-heme oxygenase-1 signaling pathway. Despite much information on the role of PPARa on renal tissue, little is known about its behavior in the kidney during the development of obesity that may result in up-or down-regulation of the expression of its target genes that can increase susceptibility to kidney disease.
In addition, PPARa exerts antioxidant effects (Kono et al. 2009; Girnun et al. 2002; Diep et al. 2002; Devchand et al. 1996) . Activation of PPARa inhibits angiotensin IIinduced activation of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) and suppressed reactive oxygen species (ROS) production in the vascular wall (Fig. 2) (Diep et al. 2002) . Furthermore, a PPRE has been identified in the promoter regions of catalase and Cu/ Zn superoxide dismutase (Cu/Zn SOD) genes that are key enzymes that reduce ROS production (Girnun et al. 2002) . Hou and collaborators showed that the PPARa agonist fenofibrate exerts a renoprotective effect against hypertensive renal injury in an animal model of spontaneous hypertension by inhibiting cell recruitment and TGF-b1 expression through suppression of NADPH oxidase activity and up-regulation of Cu/Zn SOD activity, thus inhibiting phosphorylation of p38MAPK and JNK (Hou et al. 2010) . Finally, PPARa agonists increase both LXR and ABC1 gene expression and enhanced apo A1-mediated cholesterol efflux from lipid-loaded mesangial cells, thereby attenuating renal lipotoxicity (Fig. 2) (Ruan et al. 2003 (Ruan et al. , 2008 .
PPARd
Although PPARd seems to be abundant in the kidney and ubiquitously expressed along the nephron, the role of this PPAR isoform in the kidney remains poorly understood (Guan et al. 1997; Hao et al. 2002) . PPARd may play an important role in the renal metabolic adaptation to fasting and refeeding (Escher et al. 2001) . A dramatic decrease in renal PPARd mRNA expression was observed during fasting, which was rapidly restored to control levels by refeeding. The regulation of PPARd expression may be related to metabolic fates, for example, gluconeogenesis and lipogenesis. As gluconeogenesis is increased during fasting, PPARd would be a negative regulator of this pathway. These findings suggest its involvement in metabolic kidney diseases such as diabetic nephropathy. In fact, in Akita and OVE26 mice with type I diabetes, the renal expression of PPARd is greatly suppressed, which may contribute to renal lipotoxicity due to reduced fatty acid oxidation (Fig. 2) (Proctor et al. 2006) . Consistent with this hypothesis, treatment of mesangial cells with insulin-like growth factor-1 (IGF-1), a cytokine up-regulated in the diabetic kidney (Chan et al. 2001) , enhanced triglyceride accumulation, possibly by increasing very low-density lipoprotein receptor (VLDLr) expression resulting from PPARd suppression (Berfield et al. 2006 ). These finding suggest that the reduction in renal PPARd expression possibly represents an underlying mechanism involved in diabetic kidney injury. Abundant and active PPARd is present in cultured renal medullary interstitial cells. In addition, overexpression of PPARd provides protection against hypertonicity-induced cell death in cultured medullary interstitial cells, which suggests that PPARd is an important survival factor in the kidney (Hao et al. 2002) . Letavernier et al. demonstrated that PPARd can provide strong protection against ischemia-induced renal injury as a result of its combined action on cell survival and cytoskeletal reorganization (Letavernier et al. 2005) . In addition, PPARd down-regulates the expression of the receptor for advanced glycation end products (RAGE) and proinflammatory cytokines (TNF-a, IL-1 and IL-6) in the kidney of streptozotocin-induced diabetic mice (Fig. 2) (Liang et al. 2011) . Collectively, PPARd agonists may be considered a novel means of conferring renal protection in diabetic nephropathy and other diseases.
PPARc
PPARc is expressed predominantly in adipose tissue, where it is a key regulator of adiposity differentiation, triglyceride storage, and energy homeostasis (Lehrke and Lazar 2005; Balakumar et al. 2007) In the kidney, PPARc is expressed in different cells, including the inner medullary collecting ducts, proximal tubules, thick ascending limb of Henle's loop (THAL), glomeruli and renal microvascular endothelial cells in rats (Yang et al. 1999; Satoh et al. 2004; Nicholas et al. 2001) , rabbits, and humans (Guan et al. 1997 ) Because multiple renal cell types have endogenous PPARc expression and activity, the kidney has been suggested as a direct target of PPARc agonists, and PPARc activation in the kidney may be critical for maintaining normal renal function. Since the introduction of thiazolidinediones (TZDs), insulin sensitizers in diabetic clinical treatment, the role of PPARc in the kidney and the potential for PPARc agonists as therapy for diabetic nephropathy have been extensively investigated. Some animal studies have suggested a protective effect of TZD in both diabetic and non-diabetic models of renal disease (Ma et al. 2001; McCarthy et al. 2000) . Most currently available studies demonstrate a renoprotective effect of PPARc agonists in patients with type 2 diabetes with or without hypertension, as indicated by reduced albuminuria (Yano et al. 2007; Sarafidis and Bakris 2006; Iglesias and Diez 2006) . Activation of PPARc prostaglandin J2 increased LXRa and ABCA1 gene expression and enhanced apo A1-mediated cholesterol efflux from human mesangial cells (HMC), even in the presence of IL-1b. This was supported by the observation that overexpression of PPARc by transfection enhanced LXRa and ABCA1 gene induction in HMC (Fig. 2) (Ruan et al. 2003) Obesity is frequently accompanied by renal dysfunction reflected in hypertension and renal injury. Interestingly, PPARc is a negative modulator for transcription of both angiotensin II receptor type 1 (AT1 receptor) and leptin genes, suggesting that activation of PPARc in obesity may be beneficial for blood pressure reduction associated with the down-regulation of the latter genes ( Fig. 2) (Dobrian 2006) . Additionally, PPARc is an important regulator of lipid homeostasis. PPARc controls the expression of an array of genes involved in lipogenesis and triglyceride storage. Also, TZD can suppress TGFbinduced collagen I and fibronectin production in mesangial cells (Guo et al. 2004; Zheng et al. 2002) . In contrast, stimulation of PPARc by fatty acids presented to proximal tubular cells bound to albumin results in profound apoptosis (Arici et al. 2003) . In addition, an increasing number of studies suggest that TZDs possess anti-inflammatory properties independent of their insulin-sensitizing action and protect renal function in various models of acute and chronic renal injury (Jiang et al. 1998; Ma et al. 2001; Matsuyama et al. 2005; Yang et al. 2006) . Furthermore, TZDs have been shown to reduce proteinuria and delay the progression of diabetic nephropathy independent of glycemic control (Miyazaki-Anzai et al. 2010; Okada et al. 2006) . Although PPARc is generally accepted as a renoprotective factor in type 2 diabetes mellitus, the mechanism by which it exerts these favorable effects remains unclear. Moreover, little is known about the renal expression of PPARc in chronic kidney disease. In addition, human data on PPARc expression are very scarce. An important issue to be addressed is the fact that TZD treatment frequently results in sodium and water retention, possibly by activating PPARc in the renal microvasculature smooth muscle and collecting duct. The long-term consequences of TZDassociated fluid retention on blood pressure remain to be determined.
The Liver X receptors (LXRs)
Liver X receptors (LXRs) are nuclear hormone receptors that act as transcription factors. As such, LXRs regulate the expression of genes involved in cholesterol and fatty acid metabolism (Kuipers et al. 2010; Tontonoz and Mangelsdorf 2003) . In the liver, LXRs regulate the expression of genes involved in bile acid and cholesterol metabolism, as well as the SREBP-1c, which stimulates lipogenesis via its target genes (Peet et al. 1998 ). In the macrophage, gut and other cell types and tissues, LXRs play a crucial role in reverse cholesterol transport, thereby stimulating the efflux of cholesterol from the peripheral tissue to the liver. Two different, yet highly homologous, isoforms of LXR have been described, LRX-a and LXR-b. Both LXRs heterodimerize with RXR bind to the DR-4 response element with the sequence 5 0 -GGTTTAAATAAGTTCA-3 0 in the promoter of target genes (Kuipers et al. 2010; Willy et al. 1995) . These targets include ATP-binding cassette transporters A1, G5, and G8 (ABCA1, ABCG5, ABCG8), apolipoprotein E (Apo E), cholesterol ester transport protein (CETP), lipoprotein lipase (LPL), fatty acid synthase (FAS), and SREBP-1c, suggesting that LXRs are key players in lipid and cholesterol metabolism (Steffensen and Gustafsson 2004; Ulven et al. 2005) . Natural ligands for LXRs are oxysterols, but strong synthetic agonists such as T0901317 (T09) and GW3965 have been developed. Although LXR-b is ubiquitously expressed, LXR-a is expressed mainly in the liver, adipose tissue, macrophages, intestine, spleen, kidney, and heart. A PPAR response element has been identified in the LXR gene promoter; it therefore seems likely that PPAR regulates ABCA1 gene expression through the LXR pathway (Ruan et al. 2003) .
In the kidney, LXRs are specially expressed in reninproducing juxtaglomerular (JG) cells (Morello et al. 2005) . In JG cells, renin transcriptional and translational control is meticulously regulated at multiple levels. The hormone renin is the rate-limiting step in the renin-angiotensinaldosterone system (RAAS), which is a critical regulator of blood pressure and salt-volume homeostasis in physiological and pathological conditions. LXRs have been shown to regulate renin expression in vivo, suggesting crosstalk between the RAAS and lipid metabolism (Fig. 3) . Oxidized cholesterol derivatives (oxysterols) are endogenous ligands for LXR (Janowski et al. 1996) . Thus, elevated cellular cholesterol levels lead to accumulation of these cholesterol metabolic byproducts and activation of the LXR target genes (Fig. 3) . Activation of the genes of reverse cholesterol transport by LXR increases the transport of cholesterol from peripheral tissues, including the macrophages, to the liver for catabolism and excretion (Laffitte et al. 2001; Luo and Tall 2000; Venkateswaran et al. 2000) (Fig. 3) . In addition to these processes that maintain cholesterol homeostasis, LXR-mediated gene regulation in the intestine decreases dietary cholesterol absorption (Tontonoz and Mangelsdorf 2003) . SREBP-1 up-regulation by LXR causes an increase in lipogenesis, leading to elevation of serum free fatty acids (Peet et al. 1998; Schults et al. 2000) . LXR agonists also increase murine renin gene expression in vivo, suggesting a link between cholesterol and lipid metabolism, the reninangiotensin-aldosterone system and blood pressure regulation (Morello et al. 2005) (Fig. 3) .
It has been reported that LXRs regulate renin gene expression in a ligand-independent manner by interacting with a specific responsive element in the renin promoter known as the cAMP-negative response element (CNRE) (Morello et al. 2005) . However, it has also been shown that treatment of rats with the synthetic LXR agonist GW3965 interferes with angiotensin II-mediated pressor responses (Leik et al. 2007) , suggesting that the LXR agonist may affect vascular reactivity. These observations indicate that there is crosstalk between LXR activation and RAAS activation, but it remains unknown whether long-term LXR stimulation modulates RAAS activity and, if so, which enzymes or peptides of RAAS are affected by LXR stimulation. Additionally, a study conducted by Wu et al. demonstrated that glomerular LXR a expression was markedly induced by TZD. A similar effect was observed with the use of LXR a agonist T-0901317, which markedly increased the apolipoprotein AI (Apo AI)-mediated cholesterol efflux in cultured mesangial cells, suggesting that LXR a may participate, at least in part, in cholesterol transport in renal mesangial cells (Wu et al. 2004) (Fig. 3) .
The Farnesoid X receptor (FXR)
The farnesoid X receptor (FXR) is a bile acid-activated nuclear receptor that plays an important role in regulating bile acid metabolism (Goodwin and Kliewer 2002) . FXR is a bile acid sensor and is activated by binding to endogenous bile acids (Makishima et al. 1999; Parks et al. 1999; Wang et al. 1999) . High levels of FXR have been described not only in the liver and intestine but also in the kidney and adrenals (Forman et al. 1995; Lu et al. 2001) . However, the physiological function of FXR in these tissues, which are not normally exposed to bile acid circulation, remains controversial. In the mouse kidney, FXR has been detected in both isolated glomeruli and proximal tubules. The expression level in proximal tubule cells is much higher than in glomeruli (Jiang et al. 2007 ). In addition, FXR is expressed in both cultured mouse mesangial cells and podocytes (Jiang et al. 2007) .
FXR has been shown to control lipid metabolism through a mechanism that involves repression of hepatic SREBP-1c expression (Watanabe et al. 2004; Zhang et al. 2004) (Fig. 3) . Moreover, FXR activation prevents liver fibrosis (Fiorucci et al. 2004 ) and atherosclerotic lesions (Hartman et al. 2009; Li et al. 2007) .
Jiang et al. demonstrated that C57BL76J mice treated with FXR agonist did not experience a high fat-induced increase in the renal expression of SREBP-1 (Jiang et al. 2007) (Fig. 3) . In addition, treatment of db/db mice with FXR agonists prevents the progression of proteinuria and glomerulosclerosis, the renal accumulation of triglycerides, and the increased expression of profibrotic growth factors, pro-inflammatory cytokines, and NADPH oxidase (Fig. 3) . Furthermore, cell culture studies indicate that in a highglucose milieu, FXR plays a direct role in inhibiting SREBP-1-mediated fatty acid synthesis and expression of profibrotic growth factors and pro-inflammatory cytokines. In a study conducted by Wang et al. , the investigators demonstrated the key role of FXR in modulating SREBP-1 activity, glomerular lesions, and proteinuria. They found that feeding a Western-style diet to DBA/2J mice resulted in proteinuria, product loss, mesangial expansion, renal lipid accumulation, increased expression of pro-inflammatory factors, oxidative stress, and profibrotic growth factors (Fig. 3) . Treatment of these mice with the highly selective and potent FXR-activating ligand 6-a-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress in the kidney (Fig. 3) . Additionally, FXR has been shown to negatively interfere with the inflammatory response by antagonizing the NFjB signaling pathway ) to support its role as a modulator of inflammation (Fig. 3) .
Pregnane X receptor (PXR)
The xenobiotic nuclear receptor PXR functions as an endobiotic and xenobiotic sensor that coordinately regulates drug and endogenous metabolites clearance via induction of genes coding for oxidation and conjugation enzymes (phase I and II, respectively), as well as for transporters (Francis et al. 2003) . Furthermore, transcriptional activity of this nuclear receptor is regulated by signaling pathways associated with NFjB and JNK, which are known to be induced in obesity (Cai et al. 2005; Hirosumi et al. 2002) . PXR is predominantly expressed in the liver and intestine, both of which are sites of elevated steroid xenobiotic metabolism. Nevertheless, it is also expressed to a lesser extent in the kidney and other tissues such as the stomach and lung (Kliewer et al. 1998; Miki et al. 2005; Zhang et al. 1999) , although its role in these tissues is not so well defined. Numerous structurally unrelated drugs and environmental contaminants can bind and activate PXR, including the antibiotic rifampicin and endobiotics such as precursor, intermediate and secondary bile acid metabolites. The canonical function of the PXR is therefore to sense elevations in xenobiotics and endobiotics and to orchestrate a response that promotes xenobiotic/endobiotic metabolism and excretion (Kliewer 2003) . Among the consequences of obesity are changes in the pharmacokinetics and pharmacodynamics of many therapeutic drugs, although the mechanism of obesity-mediated alterations of drug metabolism in unknown (Blouin et al. 1999; Cheymol 2000) in settings where the kidney plays a major function as the natural filter of the blood and the remover of wastes. For instance, the metabolism of acetaminophen and verapamil is altered in the kidney of obese rats Osabe et al. 2008) . Recent studies indicate that PXR can be activated by endogenous cholesterol metabolites, implicating its involvement in the clearance of potentially toxic intermediates. Cholic acid is a cholesterol metabolite and a signaling molecule known to block cholesterol catabolism. In a study conducted by Sonoda et al. in mice lacking PXR that were challenged with a diet supplemented with cholic acid, addition of cholesterol to their diet resulted in acute lethality associated with signs of hepatorenal failure (Sonoda et al. 2005) . It was speculated that the renal failure might be the direct cause of death. These results reveal an essential and unique role of PXR in the protection from cholesterol and its metabolites. Other targets of PXR include the ABCA1, as well as the scavenger receptor class B type I (SR-BI), which are both involved in the exchange of cholesterol between HDL lipoproteins and cells (Fig. 3) . Because lipid abnormalities in ESRD are characterized by reduced serum apo A-1 and HDL concentration, this in turn promotes an influx of ox-LDL in macrophages and resident cells in the artery wall and facilitates foam cell formation and atherosclerosis (Fig. 3) . For this reason, it is necessary to investigate its relationship in the kidney. In addition to playing important roles in cholesterol detoxification, PXR can also modulate SREBP-dependent and SREBP-independent lipogenic pathways in vitro and in vivo. PXR can mediate a SREBP-independent lipogenic pathway by activating the free fatty acid (FFA) uptake transporter CD36, PPARc, and several accessory lipogenic enzymes, such as stearoyl CoA desturase-1 (SCD-1) and long-chain free fatty acid elongase (FAE) (Zhou et al. 2006 ). PXR activation is also associated with induction of Insig-1, a protein with anti-lipogenic properties and with reduced protein levels of the active form of SREBP-1 (Roth et al. 2008) . A functional PXR binding site was found in the Insig-1 promoter, and it was suggested that Insig-1 expression stimulated by PXR could lead to decreased levels of active SREBP-1 and reduced triglyceride synthesis (Fig. 3) . Taken together, these studies suggest that PXR plays important roles in cholesterol metabolism and lipid homeostasis. However, the precise mechanisms by which PXR modulates lipid metabolism and cholesterol levels in vivo remains unclear, and the effects of this nuclear receptor in the kidney on lipid metabolism and its possible association with renal abnormalities are poorly defined.
Although several cholesterol metabolites, such as bile acids, bile alcohol, and epoxycholesterols, have been shown to activate PXR, there has been little evidence for the physiological or pathological importance of PXR function in their detoxification (Ambroziak et al. 2010; Cheng and Klaassen 2006; Nannelli et al. 2008; Zhang et al. 1999) . Not much is known in regard to PXR functions and its target genes in the kidney. Because lipid metabolism deregulation in the kidney has been identified as a major factor in the development of chronic kidney disease and because PXR seems to be highly implicated in the regulation of lipid metabolism, further studies are required to assess the potential role of PXR activation in the kidney for the development of chronic kidney disease.
Concluding remarks
The prevalence of obesity has risen dramatically in developing and developed countries. This phenomenon has led to an increase in the so called metabolic syndrome. The relationship between metabolic syndrome and chronic kidney disease has recently been examined (Nitta 2010; Takahashi et al. 2006 ). Several nuclear receptors can mediate some of the abnormalities that occur in the kidney during the development of metabolic syndrome. These nuclear receptors can activate genes in the kidney or in other organs that can contribute directly or indirectly to the pathophysiology of metabolic alterations present in chronic kidney diseases. For instance, the dyslipidemia associated with the progression of chronic renal failure (Fried et al. 2001) , inflammation, lipid accumulation, and foam cell formation that are features of glomerular and tubulointerstitial injury, as well as renal injury and atherosclerosis, share common pathophysiological mechanisms that involve several nuclear receptors (Moorhead et al. 1982) . Thus, the global obesity problem presents urgent demands for improved means of disease prevention through the introduction of new drugs, the improvement of diet recommendations and increased patient compliance (Seedorf and Aberle 2007) . Ligands of some of the nuclear receptors can be used as therapeutic agents to ameliorate the renal abnormalities that are frequently found in obese subjects who develop type 2 diabetes. Thus, metabolic nuclear receptors and their coregulators may be useful targets for medications. Several abnormalities in the kidney diseases that appear as a consequence of the development of metabolic syndrome are in part associated with alterations in the renal lipid metabolism. The control of renal lipid levels in situ with the use of specific ligands with a large spectrum of full, partial, or inverse agonist or antagonist activity as well as compounds called selective nuclear receptor modulators in the kidney that activate only a subset of the function induced by cognate ligand or that act in specific cell-types in the kidney can prevent or revert the rates of lipogenesis and fatty acid oxidation, resulting in an improvement of renal lipid concentrations, which has been recently considered extremely important factor to improve renal function.
